SCHEMBL15215708

SCHEMBL15215708

COC1OC(CO[C@]2(C(=O)O)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O2)[C@H](O)[C@H](O)C1C

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CD22 P20273 19/20 0.48
▸ MAG P20916 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16407968 1.00 CD22 (0.48) CD22MAG
SCHEMBL25787323 0.94 CD22 (0.51) CD22MAG
SCHEMBL12061298 0.89 CD22 (0.44) CD22MAG
SCHEMBL21334206 0.88 CD22 (0.47) CD22MAG
SCHEMBL18718069 0.88 CD22 (0.47) CD22MAG
SCHEMBL18718058 0.88 CD22 (0.47) CD22MAG
SCHEMBL18718049 0.87 CD22 (0.46) CD22MAG
SCHEMBL17853991 0.87 CD22 (0.48) CD22MAG
SCHEMBL17857272 0.87 MAG (0.46) CD22MAG
SCHEMBL17853988 0.86 CD22 (0.48) CD22MAG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023814-B2 Glycomimetic compounds as anti-infectious against pathogens lectins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-05-05 — — US disclosed
US-20140147938-A1 NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PYRENE BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2014-05-29 — — US disclosed
US-20130252910-A1 GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-09-26 — — US disclosed
US-20130224761-A1 NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PORPHYRIN BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2013-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252910-A1 GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS SIGLEC7, SIGLEC9, LGALS1 CD22 60/4885MAG 293/4885
US-20140147938-A1 NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PYRENE BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN SIGLEC7, EPCAM, LGALS1 CD22 189/4885MAG 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback